about
Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failureClinical predictors of response to anakinra in patients with heart failure.Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)Pharmacologic and surgical interventions to improve functional capacity in heart failure.Heart failure with preserved ejection fraction: refocusing on diastole.Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure.Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction.Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation.Biomarkers of cardiac injury in patients undergoing thoracic radiation therapy.Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).Severely Impaired Cardiorespiratory Fitness in Patients With Recently Decompensated Systolic Heart Failure.Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.Letter by Carbone et al Regarding Article, "Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction".Exercise Capacity in Patients with the Total Artificial Heart.Colchicine in Stable Chronic Heart FailureEffect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical TrialsEffects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diureticsIncreased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy
P50
Q28731260-ADEAA9FF-86AE-4C80-9879-8B71CB83C8E3Q35898868-14A77C50-DFE0-4D48-85FB-6787A2E6A282Q36985609-78DFA573-C79F-4C4D-88B9-9448B88CA7F9Q38272433-138588EA-9A40-4CF0-9F12-06E667EF7685Q38281338-C7AEA1AF-5220-4CE5-BA4A-C260E1B3D64EQ40346820-A42DEB43-E77D-4516-837E-508AB9B61E2EQ41239103-BE797814-6CAA-4D57-97B5-B6DBCFE805E6Q44968605-F5CBAC11-ED3C-4A67-B0F2-C5A2A3442D53Q45040846-34D15F5D-3851-4C38-94B6-32E0D15271BDQ45058507-198CFAD9-62AE-4B2A-A0B5-629507DC8041Q45066447-CB6A0531-58C4-414A-BD48-30E0E8AE01ECQ45073053-0B46CEF7-F2A4-4D7F-9300-1206584B1D86Q47096165-83AB9078-8BE9-434A-9661-F457C9009CD8Q47854367-E67F26ED-1F81-4EB9-ACBF-852EB2E25456Q49874308-AFE5D3E6-0248-4E67-9C5A-A6D08AFC3B9FQ50086921-9054D4C1-F50E-44FE-BF0F-EF816D5EFCBBQ56796269-86A2CEFE-39E8-402C-8238-141FEAB87375Q60177543-9B96C194-95CB-437E-AC91-272BD324777EQ88231385-5584B17F-455A-4033-B43E-193461866F39Q90178740-1ADB6466-3477-4D9A-904D-FCE1DD5D86A5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Justin Canada
@ast
Justin Canada
@en
Justin Canada
@es
Justin Canada
@nl
type
label
Justin Canada
@ast
Justin Canada
@en
Justin Canada
@es
Justin Canada
@nl
prefLabel
Justin Canada
@ast
Justin Canada
@en
Justin Canada
@es
Justin Canada
@nl
P106
P21
P31
P496
0000-0002-1342-7463